Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan Establishes Public-Private Biopharmaceutical Partnership

This article was originally published in PharmAsia News

Executive Summary

Japan's Ministry of Economy, Trade and Industry released a plan April 20 to establish a public-private partnership to stimulate biopharmaceutical industry growth

Japan's Ministry of Economy, Trade and Industry released a plan April 20 to establish a public-private partnership to stimulate biopharmaceutical industry growth.

The partnership plans to invest ¥3 billion and set up a company within the year to support biopharmaceutical development. The new policy is to help fund research of molecular target candidates among Japanese biotech venture companies and provide equipment and human resource assistance. The ministry also plans to jointly work with the Ministry of Health to nurture the biopharma industry. (Click here for more - Japanese language)

"Public-Private Partnership To Funds Biopharma Research And Development"--Mainichi News (4/20/2010)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC074626

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel